Tandem Diabetes Care (TNDM) Q3 2026: Profit Breakeven in Sight
As seen on the 24/7 Wall St. homepage on November 5, 2026.
Tandem is within striking distance of breakeven: the operating loss narrowed to $2.4 million from $22.9 million a year ago. Full-year guidance of $1.065 billion to $1.085 billion was reaffirmed.
Continue ReadingShow less
Tandem Diabetes Care posted a GAAP loss of $0.10 per share in Q3 2026, beating the consensus estimate of $0.24. Revenue came in at $283.69 million, topping analyst expectations of $265.85 million and rising 13.8% from the same quarter a year ago. Those twin beats mark a meaningful step forward for a company that has spent years working to prove its insulin pump business can eventually sustain itself without outside capital.
The most striking detail in the report is how close the company came to operating breakeven. The operating loss narrowed to $2.4 million from $22.9 million a year ago, a swing driven by a 270-basis-point expansion in gross margin to 57% and relatively stable operating expenses. For a medical device company still investing heavily in its platform and international expansion, that kind of leverage on the income statement is a material change in the story.
Geographic diversification is becoming a real strength. International sales rose 26% to $92.64 million, while U.S. supplies and other revenue jumped 19% to $107.66 million. The growth in U.S. supplies is tied directly to Tandem's pay-as-you-go pharmacy reimbursement model, which now covers roughly 50% of U.S. lives and builds a predictable recurring revenue base that is less dependent on new pump shipments.
Sponsored
U.S. pump sales did slip 2% year over year, a reflection of the ongoing transition as more customers shift toward the pharmacy channel rather than traditional durable medical equipment reimbursement. Tandem shipped approximately 33,000 pumps worldwide in the quarter, with volume up in both the U.S. and international markets, so the revenue dip in that segment appears to be more a mix and timing issue than a demand problem.
Management reaffirmed full-year 2026 guidance calling for sales of $1.065 billion to $1.085 billion, including U.S. sales of $730 million to $745 million and international sales of $335 million to $340 million. The company also maintained its adjusted EBITDA margin target of 5% to 6% for the full year. With free cash flow still negative and total liabilities at $1.02 billion, the path to sustainable profitability remains the central question investors will keep measuring each quarter.
Mentioned: TNDM